NASDAQ:QNTM Quantum Biopharma (QNTM) Stock Price, News & Analysis $3.66 -0.06 (-1.61%) Closing price 09/18/2026 04:00 PM EasternExtended Trading$3.66 0.00 (0.00%) As of 09/18/2026 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsNews and TrendsOwnershipSEC Filings About Quantum Biopharma Stock (NASDAQ:QNTM) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Quantum Biopharma alerts:Sign Up Key Stats Today's Range$3.62▼$3.8350-Day Range$2.83▼$3.8052-Week Range$2.07▼$21.00Volume95,046 shsAverage Volume144,261 shsMarket Capitalization$23.42 millionP/E RatioN/ADividend YieldN/APrice Target$8.00Consensus RatingHold Company Overview Quantum BioPharma Inc. (NASDAQ:QNTM), formerly known as FSD Pharma Inc., is a biotechnology company developing therapeutics for neurodegenerative and other serious medical conditions. The company’s research pipeline is centered on novel small-molecule compounds intended to address diseases involving myelin damage and related neurological dysfunction. Its lead investigational program, Lucid-MS, is being developed as a potential treatment for multiple sclerosis. The compound is designed to target processes associated with demyelination and may also support remyelination, although it remains under development and has not been approved for commercial use. Quantum BioPharma has also pursued research related to alcohol use disorder and other central nervous system conditions. The company has additionally been involved in consumer health initiatives through products such as UNBUZZD, a functional beverage marketed for use after alcohol consumption. Quantum BioPharma is based in North America and has historically operated across the Canadian and U.S. biotechnology and capital markets. The company adopted its current name from FSD Pharma as part of a broader strategic repositioning toward biotechnology and pharmaceutical development.AI Generated. May Contain Errors. Read More Quantum Biopharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks53rd Percentile Overall ScoreQNTM MarketRank™: Quantum Biopharma scored higher than 53% of companies evaluated by MarketBeat, and ranked 440th out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingHold Consensus RatingQuantum Biopharma has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.Upside PotentialQuantum Biopharma has a consensus price target of $8.00, representing about 118.6% upside from its current price of $3.66.Amount of Analyst CoverageQuantum Biopharma has only been the subject of 2 research reports in the past 90 days.Read more about Quantum Biopharma's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Quantum Biopharma is -0.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Quantum Biopharma is -0.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioQuantum Biopharma has a P/B Ratio of 2.73. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Quantum Biopharma's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.46% of the float of Quantum Biopharma has been sold short.Short Interest Ratio / Days to CoverQuantum Biopharma has a short interest ratio ("days to cover") of 1.07, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Quantum Biopharma has recently decreased by 10.35%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldQuantum Biopharma does not currently pay a dividend.Dividend GrowthQuantum Biopharma does not have a long track record of dividend growth. News and Social Media2.7 / 5News Sentiment0.30 News SentimentQuantum Biopharma has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Quantum Biopharma this week, compared to 3 articles on an average week.Search Interest6 people have searched for QNTM on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Quantum Biopharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -78% compared to the previous 30 days. Company Ownership0.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Quantum Biopharma insiders have not sold or bought any company stock.Percentage Held by Insiders8.53% of the stock of Quantum Biopharma is held by insiders.Percentage Held by Institutions1.24% of the stock of Quantum Biopharma is held by institutions.Read more about Quantum Biopharma's insider trading history. Receive QNTM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Quantum Biopharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. QNTM Stock News HeadlinesQuantum BioPharma (NASDAQ: QNTM) Announces that Rodman & Renshaw Initiates Coverage with Buy Rating, $8 Price TargetSeptember 17 at 2:05 PM | markets.businessinsider.comRodman & Renshaw Initiates Analyst Coverage on Quantum BioPharma with a BUY Rating and US$8 Price TargetSeptember 17 at 8:00 AM | globenewswire.comHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required. | Stansberry Research (Ad)Quantum BioPharma (QNTM) to Present at 3rd Annual ArcStone-Kingswood Growth SummitSeptember 15, 2026 | finance.yahoo.comQuantum BioPharma (NASDAQ: QNTM) to Present at 3rd Annual ArcStone-Kingswood Growth SummitSeptember 15, 2026 | markets.businessinsider.comNetworkNewsAudio Announces Audio Press Release (APR) Discussing FDA Clearance for Trial of First-in-Class Treatment Creating ‘Rare Moment’ in MS ResearchSeptember 14, 2026 | theglobeandmail.comNetworkNewsAudio Announces Audio Press Release (APR) Discussing FDA Clearance for Trial of First-in-Class Treatment Creating ‘Rare Moment' in MS ResearchSeptember 14, 2026 | globenewswire.comQuantum BioPharma Ltd. (NASDAQ: QNTM) Filling Key Gap in MS Treatment, Cleared by FDA to Launch Historic TrialsSeptember 11, 2026 | globenewswire.comSee More Headlines QNTM Stock Analysis - Frequently Asked Questions How have QNTM shares performed this year? Quantum Biopharma's stock was trading at $7.30 at the beginning of 2026. Since then, QNTM stock has decreased by 49.9% and is now trading at $3.66. How were Quantum Biopharma's earnings last quarter? Quantum Biopharma Ltd. (NASDAQ:QNTM) posted its quarterly earnings results on Thursday, August, 13th. The company reported ($0.47) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.41) by $0.06. How do I buy shares of Quantum Biopharma? Shares of QNTM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Quantum Biopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Quantum Biopharma investors own include Jiuzi (JZXN), Aethlon Medical (AEMD), Aditxt (ADTX), Adial Pharmaceuticals (ADIL), Ainos (AIMD) and AMC Entertainment (AMC). Company Calendar Last Earnings8/13/2026Today9/19/2026Next Earnings (Estimated)11/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (3m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 QNTM's financial health is in the Yellow zone, according to TradeSmith. QNTM has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:QNTM Previous SymbolNASDAQ:QNTM CIK1771885 Webwww.quantumbiopharma.com Phone416-854-8884FaxN/AEmployees7Year FoundedN/APrice Target and Rating Average Price Target for Quantum Biopharma$8.00 High Price Target$8.00 Low Price Target$8.00 Potential Upside/Downside+118.6%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($5.49) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$26.17 million Net MarginsN/A Pretax MarginN/A Return on Equity-582.23% Return on Assets-184.20% Debt Debt-to-Equity RatioN/A Current Ratio1.20 Quick Ratio1.19 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.34 per share Price / Book2.73Miscellaneous Outstanding Shares6,400,000Free Float5,853,000Market Cap$23.42 million OptionableN/A Beta0.45 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NASDAQ:QNTM) was last updated on 9/20/2026 by MarketBeat.com Staff. From Our Partners“Elon’s nightmare” could fund your retirementMarc Chaikin, the 60 year Wall Street veteran whose Chaikin Money Flow indicator sits on every Bloomberg termi...Chaikin Analytics | SponsoredYou’ve never seen anything like this beforeFor centuries, families like the Rothschilds, Morgans, and Rockefellers have quietly used one overlooked type ...Porter & Company | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredNVDA CEO says it’s a "once-in-a-generation opportunity"NVIDIA CEO Jensen Huang calls a little-known AI niche a once-in-a-generation opportunity, and it has nothing t...Monument Traders Alliance | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredA “bloodbath” Is ComingReports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...TradeSmith | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Quantum Biopharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Quantum Biopharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
